{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T01:52:52Z","timestamp":1781574772490,"version":"3.54.5"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China,China","doi-asserted-by":"crossref","award":["12331018"],"award-info":[{"award-number":["12331018"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["12061079"],"award-info":[{"award-number":["12061079"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Project of Top-notch Talents of Technological Youth of Xinjiang, China","award":["2022TSYCCX0108"],"award-info":[{"award-number":["2022TSYCCX0108"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Syst Biol Appl"],"DOI":"10.1038\/s41540-026-00695-2","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T14:46:00Z","timestamp":1776350760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multiscale modeling reveals synergy between CCL19 and PD-1 blockade in reshaping the TNBC microenvironment"],"prefix":"10.1038","volume":"12","author":[{"given":"Chunjie","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhi","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"695_CR1","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E. & Gianni, L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol. 13, 674\u2013690 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"695_CR2","first-page":"e108","volume":"382","author":"B Cetin","year":"2020","unstructured":"Cetin, B. & Gumusay, O. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 382, e108 (2020).","journal-title":"N. Engl. J. Med."},{"key":"695_CR3","doi-asserted-by":"publisher","first-page":"vi35","DOI":"10.1093\/annonc\/mds193","volume":"23","author":"G Von Minckwitz","year":"2012","unstructured":"Von Minckwitz, G. & Martin, M. Neoadjuvant treatments for triple-negative breast cancer (TNBC). Ann. Oncol. 23, vi35\u2013vi39 (2012).","journal-title":"Ann. Oncol."},{"key":"695_CR4","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1038\/s41591-025-03734-3","volume":"31","author":"M Gion","year":"2025","unstructured":"Gion, M. et al. Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: The ATRACTIB phase 2 trial. Nat. Med. 31, 2746\u20132754 (2025).","journal-title":"Nat. Med."},{"key":"695_CR5","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-12-1362","volume":"18","author":"DS Chen","year":"2012","unstructured":"Chen, D. S., Irving, B. A. & Hodi, F. S. Molecular pathways: next-generation immunotherapy\u2014inhibiting programmed death-ligand 1 and programmed death-1. Clin. Cancer Res. 18, 6580\u20136587 (2012).","journal-title":"Clin. Cancer Res."},{"key":"695_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00486-y","volume":"8","author":"Y Abdou","year":"2022","unstructured":"Abdou, Y. et al. Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors. NPJ Breast Cancer 8, 121 (2022).","journal-title":"NPJ Breast Cancer"},{"key":"695_CR7","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","volume":"54","author":"AJ Ozga","year":"2021","unstructured":"Ozga, A. J., Chow, M. T. & Luster, A. D. Chemokines and the immune response to cancer. Immunity 54, 859\u2013874 (2021).","journal-title":"Immunity"},{"key":"695_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.immuni.2005.02.010","volume":"22","author":"BJ Marsland","year":"2005","unstructured":"Marsland, B. J. et al. CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. Immunity 22, 493\u2013505 (2005).","journal-title":"Immunity"},{"key":"695_CR9","doi-asserted-by":"publisher","first-page":"12369","DOI":"10.18632\/aging.205184","volume":"15","author":"Q Gu","year":"2023","unstructured":"Gu, Q. et al. CCL19: A novel prognostic chemokine modulates the tumor immune microenvironment and outcomes of cancers. Aging 15, 12369 (2023).","journal-title":"Aging"},{"key":"695_CR10","doi-asserted-by":"publisher","first-page":"2100715","DOI":"10.1002\/adfm.202100715","volume":"31","author":"T Yu","year":"2021","unstructured":"Yu, T. et al. Synergy of immunostimulatory genetherapy with immune checkpoint blockade motivates immune response to eliminate cancer. Adv. Funct. Mater. 31, 2100715 (2021).","journal-title":"Adv. Funct. Mater."},{"key":"695_CR11","doi-asserted-by":"publisher","first-page":"373\u2013393.e8","DOI":"10.1016\/j.medj.2023.04.008","volume":"4","author":"S-Y Wu","year":"2023","unstructured":"Wu, S.-Y. et al. CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer. Med 4, 373\u2013393.e8 (2023).","journal-title":"Med"},{"key":"695_CR12","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.18632\/aging.204081","volume":"14","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. CCL19 has potential to be a potential prognostic biomarker and a modulator of tumor immune microenvironment (TIME) of breast cancer: A comprehensive analysis based on TCGA database. Aging 14, 4158 (2022).","journal-title":"Aging"},{"key":"695_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-022-00247-4","volume":"8","author":"R Yue","year":"2022","unstructured":"Yue, R. & Dutta, A. Computational systems biology in disease modeling and control, review and perspectives. npj Syst. Biol. Appl. 8, 37 (2022).","journal-title":"npj Syst. Biol. Appl."},{"key":"695_CR14","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1007\/s11538-016-0214-9","volume":"78","author":"R Eftimie","year":"2016","unstructured":"Eftimie, R., Gillard, J. J. & Cantrell, D. A. Mathematical models for immunology: Current state of the art and future research directions. Bull. Math. Biol. 78, 2091\u20132134 (2016).","journal-title":"Bull. Math. Biol."},{"key":"695_CR15","doi-asserted-by":"publisher","first-page":"5534","DOI":"10.1073\/pnas.1721559115","volume":"115","author":"X Lai","year":"2018","unstructured":"Lai, X. et al. Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. Proc. Natl. Acad. Sci. USA 115, 5534\u20135539 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"695_CR16","doi-asserted-by":"publisher","first-page":"106714","DOI":"10.1016\/j.isci.2023.106714","volume":"26","author":"W He","year":"2023","unstructured":"He, W., Demas, D. M., Shajahan-Haq, A. N. & Baumann, W. T. Modeling breast cancer proliferation, drug synergies, and alternating therapies. iScience 26, 106714 (2023).","journal-title":"iScience"},{"key":"695_CR17","doi-asserted-by":"publisher","first-page":"240718","DOI":"10.1098\/rsos.240718","volume":"11","author":"N Mohammad Mirzaei","year":"2024","unstructured":"Mohammad Mirzaei, N., Kevrekidis, P. G. & Shahriyari, L. Oxygen, angiogenesis, cancer and immune interplay in breast tumour microenvironment: a computational investigation. R. Soc. Open Sci. 11, 240718 (2024).","journal-title":"R. Soc. Open Sci."},{"key":"695_CR18","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/cpt.1778","volume":"107","author":"TM Polasek","year":"2020","unstructured":"Polasek, T. M. & Rostami-Hodjegan, A. Virtual twins: understanding the data required for model-informed precision dosing. Clin. Pharmacol. Ther. 107, 742\u2013745 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"key":"695_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1021\/acsptsci.0c00178","volume":"4","author":"H Ma","year":"2020","unstructured":"Ma, H., Pilvankar, M., Wang, J., Giragossian, C. & Popel, A. S. Quantitative systems pharmacology modeling of pbmc-humanized mouse to facilitate preclinical immuno-oncology drug development. ACS Pharmacol. Transl. Sci. 4, 213\u2013225 (2020).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"695_CR20","doi-asserted-by":"crossref","unstructured":"Surendran, A. et al. Approaches to generating virtual patient cohorts with applications in oncology. in Personalized Medicine Meets Artificial Intelligence: Beyond \u201cHype\u201d, Towards the Metaverse, 97\u2013119 (Springer, 2023).","DOI":"10.1007\/978-3-031-32614-1_8"},{"key":"695_CR21","doi-asserted-by":"publisher","first-page":"e002100","DOI":"10.1136\/jitc-2020-002100","volume":"9","author":"H Wang","year":"2021","unstructured":"Wang, H., Ma, H., Sov\u00e9, R. J., Emens, L. A. & Popel, A. S. Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer. J. ImmunoTher. Cancer 9, e002100 (2021).","journal-title":"J. ImmunoTher. Cancer"},{"key":"695_CR22","doi-asserted-by":"publisher","first-page":"e2410911121","DOI":"10.1073\/pnas.2410911121","volume":"121","author":"T Arulraj","year":"2024","unstructured":"Arulraj, T. et al. Virtual patient analysis identifies strategies to improve the performance of predictive biomarkers for PD-1 blockade. Proc. Natl. Acad. Sci. USA 121, e2410911121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"695_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s11538-024-01329-6","volume":"86","author":"C Li","year":"2024","unstructured":"Li, C., Ren, Z., Yang, G. & Lei, J. Mathematical modeling of tumor immune interactions: the role of anti-FGFR and anti-PD-1 in the combination therapy. Bull. Math. Biol. 86, 116 (2024).","journal-title":"Bull. Math. Biol."},{"key":"695_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-025-00513-1","volume":"11","author":"C Li","year":"2025","unstructured":"Li, C., Wei, Y. & Lei, J. Quantitative cancer-immunity cycle modeling for predicting disease progression in advanced metastatic colorectal cancer. npj Syst. Biol. Appl. 11, 33 (2025).","journal-title":"npj Syst. Biol. Appl."},{"key":"695_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-024-00714-6","volume":"12","author":"Z Guo","year":"2024","unstructured":"Guo, Z. et al. Tumor microenvironment and immunotherapy for triple-negative breast cancer. Biomark. Res. 12, 1\u201319 (2024).","journal-title":"Biomark. Res."},{"key":"695_CR26","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","volume":"21","author":"S Jhunjhunwala","year":"2021","unstructured":"Jhunjhunwala, S., Hammer, C. & Delamarre, L. Antigen presentation in cancer: Insights into tumour immunogenicity and immune evasion. Nat. Rev. Cancer 21, 298\u2013312 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"695_CR27","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.3390\/cancers13164233","volume":"13","author":"JJ Li","year":"2021","unstructured":"Li, J. J., Tsang, J. Y. & Tse, G. M. Tumor microenvironment in breast cancer\u2014updates on therapeutic implications and pathologic assessment. Cancers 13, 4233 (2021).","journal-title":"Cancers"},{"key":"695_CR28","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman, I., Chen, D. S., Powles, T. & Turley, S. J. The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity 56, 2188\u20132205 (2023).","journal-title":"Immunity"},{"key":"695_CR29","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/s41590-023-01510-4","volume":"24","author":"M K\u00fcnzli","year":"2023","unstructured":"K\u00fcnzli, M. & Masopust, D. CD4+ T cell memory. Nat. Immunol. 24, 903\u2013914 (2023).","journal-title":"Nat. Immunol."},{"key":"695_CR30","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","volume":"24","author":"MA Harris","year":"2024","unstructured":"Harris, M. A. et al. Towards targeting the breast cancer immune microenvironment. Nat. Rev. Cancer 24, 554\u2013577 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"695_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0778-6","volume":"12","author":"Q Wu","year":"2019","unstructured":"Wu, Q. et al. Cancer-associated adipocytes: Key players in breast cancer progression. J. Hematol. Oncol. 12, 1\u201315 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"695_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41540-024-00435-4","volume":"10","author":"E Kara","year":"2024","unstructured":"Kara, E., Jackson, T. L., Jones, C. & Sison, R. R. L. M. Mathematical modeling insights into improving CAR T cell therapy for solid tumors with bystander effects. npj. Syst. Biol. Appl. 10, 105 (2024).","journal-title":"Syst. Biol. Appl."},{"key":"695_CR33","doi-asserted-by":"publisher","first-page":"e000582","DOI":"10.1136\/jitc-2020-000582","volume":"8","author":"Y Iida","year":"2020","unstructured":"Iida, Y. et al. Local injection of CCL19-expressing mesenchymal stem cells augments the therapeutic efficacy of anti-PD-L1 antibody by promoting infiltration of immune cells. J. Immunother. Cancer 8, e000582 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"695_CR34","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/sj.cgt.7701042","volume":"14","author":"J Westermann","year":"2007","unstructured":"Westermann, J. et al. CCL19 (ELC) as an adjuvant for DNA vaccination: Induction of a TH1-type T-cell response and enhancement of antitumor immunity. Cancer Gene Ther. 14, 523\u2013532 (2007).","journal-title":"Cancer Gene Ther."},{"key":"695_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-017-0243-4","volume":"5","author":"S Gnjatic","year":"2017","unstructured":"Gnjatic, S. et al. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J. Immunother. Cancer 5, 1\u201318 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"695_CR36","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1054\/mehy.2001.1536","volume":"58","author":"HP Singh","year":"2002","unstructured":"Singh, H. P., Gupta, S. & Raina, V. Restoration of naive cell repertoire in the appropriate cytokine milieu: a model for preventing cancer relapses. Med. Hypotheses 58, 554\u2013557 (2002).","journal-title":"Med. Hypotheses"},{"key":"695_CR37","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/j.jcyt.2024.03.050","volume":"26","author":"Z Dai","year":"2024","unstructured":"Dai, Z., Kim, S., Grier, S. & Singh, A. Programming na\u00efve primary T cells for enhanced immunotherapy. Cytotherapy 26, S29\u2013S30 (2024).","journal-title":"Cytotherapy"},{"key":"695_CR38","doi-asserted-by":"crossref","unstructured":"Wa\u0142ajtys-Rode, E. & Dzik, J. M. Monocyte\/Macrophage: NK cell cooperation\u2014old tools for new functions. Results Probl. Cell Differ. 62, 73\u2013145 (2017).","DOI":"10.1007\/978-3-319-54090-0_5"},{"key":"695_CR39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S1074-7613(03)00178-X","volume":"19","author":"PR Taylor","year":"2003","unstructured":"Taylor, P. R. & Gordon, S. Monocyte heterogeneity and innate immunity. Immunity 19, 2\u20134 (2003).","journal-title":"Immunity"},{"key":"695_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00522-z","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang, S. et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. npj Precis. Oncol. 8, 31 (2024).","journal-title":"npj Precis. Oncol."},{"key":"695_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04882-x","volume":"13","author":"S Liu","year":"2022","unstructured":"Liu, S. et al. CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer. Cell Death Dis. 13, 441 (2022).","journal-title":"Cell Death Dis."},{"key":"695_CR42","doi-asserted-by":"publisher","first-page":"e20240445","DOI":"10.1084\/jem.20240445","volume":"222","author":"S-N Tan","year":"2025","unstructured":"Tan, S.-N. et al. Regulatory T cells converted from Th1 cells in tumors suppress cancer immunity via CD39. J. Exp. Med. 222, e20240445 (2025).","journal-title":"J. Exp. Med."},{"key":"695_CR43","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow, D. B. et al. Pd-l1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 18, 345\u2013362 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"695_CR44","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","volume":"2","author":"L Vanhersecke","year":"2021","unstructured":"Vanhersecke, L. et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat. Cancer 2, 794\u2013802 (2021).","journal-title":"Nat. Cancer"},{"key":"695_CR45","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.ccell.2024.07.006","volume":"42","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Ccl19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis. Cancer Cell 42, 1370\u20131385 (2024).","journal-title":"Cancer Cell"},{"key":"695_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59341-w","volume":"16","author":"H Li","year":"2025","unstructured":"Li, H. et al. Mature tertiary lymphoid structures evoke intra-tumoral T and B cell responses via progenitor exhausted CD4+ T cells in head and neck cancer. Nat. Commun. 16, 4228 (2025).","journal-title":"Nat. Commun."},{"key":"695_CR47","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s10238-024-01404-1","volume":"24","author":"C Qi","year":"2024","unstructured":"Qi, C. et al. Current status and progress of PD-L1 detection: Guiding immunotherapy for non-small cell lung cancer. Clin. Exp. Med. 24, 162 (2024).","journal-title":"Clin. Exp. Med."},{"key":"695_CR48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41392-020-00261-0","volume":"5","author":"J Dai","year":"2020","unstructured":"Dai, J. et al. Exosomes: key players in cancer and potential therapeutic strategy. Signal Transduct. Target. Ther. 5, 145 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"695_CR49","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nm0202-185","volume":"8","author":"L Liu","year":"2002","unstructured":"Liu, L. et al. Visualization and quantification of T cell\u2013mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat. Med. 8, 185 (2002).","journal-title":"Nat. Med."},{"key":"695_CR50","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1146\/annurev.immunol.21.120601.141110","volume":"21","author":"RH Schwartz","year":"2003","unstructured":"Schwartz, R. H. T cell anergy. Annu. Rev. Immunol. 21, 305\u2013334 (2003).","journal-title":"Annu. Rev. Immunol."},{"key":"695_CR51","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"695_CR52","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","volume":"6","author":"R Nanda","year":"2020","unstructured":"Nanda, R. et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized i-Spy2 trial. JAMA Oncol. 6, 676\u2013684 (2020).","journal-title":"JAMA Oncol."},{"key":"695_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00698-4","volume":"10","author":"J Dixon-Douglas","year":"2024","unstructured":"Dixon-Douglas, J. et al. Sustained lymphocyte decreases after treatment for early breast cancer. npj Breast Cancer 10, 94 (2024).","journal-title":"npj Breast Cancer"},{"key":"695_CR54","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","volume":"23","author":"L Galluzzi","year":"2024","unstructured":"Galluzzi, L., Guilbaud, E., Schmidt, D., Kroemer, G. & Marincola, F. M. Targeting immunogenic cell stress and death for cancer therapy. Nat. Rev. Drug Discov. 23, 445\u2013460 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"695_CR55","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1182\/blood-2005-12-4827","volume":"108","author":"GH Cornish","year":"2006","unstructured":"Cornish, G. H., Sinclair, L. V. & Cantrell, D. A. Differential regulation of T-cell growth by IL-2 and IL-15. Blood 108, 600\u2013608 (2006).","journal-title":"Blood"},{"key":"695_CR56","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41577-022-00796-z","volume":"23","author":"BG Nixon","year":"2023","unstructured":"Nixon, B. G., Gao, S., Wang, X. & Li, M. O. TGF\u03b2 control of immune responses in cancer: a holistic immuno-oncology perspective. Nat. Rev. Immunol. 23, 346\u2013362 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"695_CR57","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1600-065X.2008.00706.x","volume":"226","author":"DM Mosser","year":"2008","unstructured":"Mosser, D. M. & Zhang, X. Interleukin-10: new perspectives on an old cytokine. Immunol. Rev. 226, 205\u2013218 (2008).","journal-title":"Immunol. Rev."},{"key":"695_CR58","doi-asserted-by":"publisher","first-page":"100508","DOI":"10.1016\/j.coisb.2024.100508","volume":"37","author":"P Harlapur","year":"2024","unstructured":"Harlapur, P., Duddu, A. S. & Jolly, M. K. Dynamics of t-helper cell differentiation and plasticity: how have computational models improved our understanding? Curr. Opin. Syst. Biol. 37, 100508 (2024).","journal-title":"Curr. Opin. Syst. Biol."},{"key":"695_CR59","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jmcb\/mjr033","volume":"4","author":"DQ Tran","year":"2012","unstructured":"Tran, D. Q. TGF-\u03b2: The sword, the wand, and the shield of FOXP3+ regulatory T cells. J. Mol. Cell. Biol. 4, 29\u201337 (2012).","journal-title":"J. Mol. Cell. Biol."},{"key":"695_CR60","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1182\/blood-2009-05-219584","volume":"114","author":"G Lal","year":"2009","unstructured":"Lal, G. & Bromberg, J. S. Epigenetic mechanisms of regulation of Foxp3 expression. Blood 114, 3727\u20133735 (2009).","journal-title":"Blood"},{"key":"695_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11782-w","volume":"10","author":"Z Sun","year":"2019","unstructured":"Sun, Z. et al. A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control. Nat. Commun. 10, 3874 (2019).","journal-title":"Nat. Commun."},{"key":"695_CR62","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","volume":"9","author":"S Chen","year":"2024","unstructured":"Chen, S., Zhu, H. & Jounaidi, Y. Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization. Signal Transduct. Target. Ther. 9, 302 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"695_CR63","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41388-018-0477-8","volume":"38","author":"H Goto","year":"2019","unstructured":"Goto, H. et al. Adipose-derived stem cells enhance human breast cancer growth and cancer stem cell-like properties through adipsin. Oncogene 38, 767\u2013779 (2019).","journal-title":"Oncogene"},{"key":"695_CR64","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2159-8290.CD-20-0655","volume":"11","author":"B C\u00f3zar","year":"2021","unstructured":"C\u00f3zar, B. et al. Tumor-infiltrating natural killer cells. Cancer Discov. 11, 34\u201344 (2021).","journal-title":"Cancer Discov."},{"key":"695_CR65","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","volume":"192","author":"SA Rosenberg","year":"2014","unstructured":"Rosenberg, S. A. IL-2: The first effective immunotherapy for human cancer. J. Immunol. 192, 5451\u20135458 (2014).","journal-title":"J. Immunol."},{"key":"695_CR66","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.trecan.2023.05.003","volume":"9","author":"MA Salkeni","year":"2023","unstructured":"Salkeni, M. A. & Naing, A. Interleukin-10 in cancer immunotherapy: from bench to bedside. Trends Cancer 9, 716\u2013725 (2023).","journal-title":"Trends Cancer"},{"key":"695_CR67","doi-asserted-by":"publisher","first-page":"106939","DOI":"10.1016\/j.intimp.2020.106939","volume":"88","author":"L Li","year":"2020","unstructured":"Li, L. et al. Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment. Int. Immunopharmacol. 88, 106939 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"695_CR68","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-94-024-0921-5_6","volume":"941","author":"H Zheng","year":"2016","unstructured":"Zheng, H., Ban, Y., Wei, F. & Ma, X. Regulation of interleukin-12 production in antigen-presenting cells. Adv. Exp. Med. Biol. 941, 117\u2013138 (2016).","journal-title":"Adv. Exp. Med. Biol."},{"key":"695_CR69","doi-asserted-by":"publisher","first-page":"7493","DOI":"10.3390\/ijms24087493","volume":"24","author":"Q Zhang","year":"2023","unstructured":"Zhang, Q. & Sioud, M. Tumor-associated macrophage subsets: shaping polarization and targeting. Int. J. Mol. Sci. 24, 7493 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"695_CR70","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc2628","volume":"9","author":"F Balkwill","year":"2009","unstructured":"Balkwill, F. Tumour necrosis factor and cancer. Nat. Rev. Cancer 9, 361\u2013371 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"695_CR71","doi-asserted-by":"publisher","first-page":"101280","DOI":"10.1016\/j.smim.2019.05.002","volume":"43","author":"JD Burke","year":"2019","unstructured":"Burke, J. D. & Young, H. A. IFN-\u03b3: a cytokine at the right time, is in the right place. Semin. Immunol. 43, 101280 (2019).","journal-title":"Semin. Immunol."},{"key":"695_CR72","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo, D. G. & Ruffell, B. Macrophages as regulators of tumour immunity and immunotherapy. Nat. Rev. Immunol. 19, 369\u2013382 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"695_CR73","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman, W. H., Pag\u00e8s, F., Saut\u00e8s-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298\u2013306 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"695_CR74","unstructured":"GeneCards Team. CCL19 Gene - C-C Motif Chemokine Ligand 19. (Accessed 30 March 2025). https:\/\/www.genecards.org\/cgi-bin\/carddisp.pl?gene=CCL19 (2025)."},{"key":"695_CR75","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12064-024-00428-1","volume":"144","author":"Z Zhang","year":"2025","unstructured":"Zhang, Z., Liang, X., Qin, J. & Lei, J. Mathematical model of tumor immune microenvironment with application to the combined therapy targeting the pd-1\/pd-l1 pathway and IL-10 cytokine antibody. Theory Biosci. 144, 19\u201343 (2025).","journal-title":"Theory Biosci."},{"key":"695_CR76","doi-asserted-by":"publisher","first-page":"108868","DOI":"10.1016\/j.mbs.2022.108868","volume":"350","author":"Y Chen","year":"2022","unstructured":"Chen, Y. & Lai, X. Modeling the effect of gut microbiome on therapeutic efficacy of immune checkpoint inhibitors against cancer. Math. Biosci. 350, 108868 (2022).","journal-title":"Math. Biosci."},{"key":"695_CR77","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00285-023-02027-y","volume":"88","author":"HG Anderson","year":"2024","unstructured":"Anderson, H. G. et al. Global stability and parameter analysis reinforce therapeutic targets of PD-L1-PD-1 and MDSCs for glioblastoma. J. Math. Biol. 88, 10 (2024).","journal-title":"J. Math. Biol."},{"key":"695_CR78","doi-asserted-by":"publisher","first-page":"111437","DOI":"10.1016\/j.jtbi.2023.111437","volume":"563","author":"P Khalili","year":"2023","unstructured":"Khalili, P. & Vatankhah, R. Studying the importance of regulatory t cells in chemoimmunotherapy mathematical modeling and proposing new approaches for developing a mathematical dynamic of cancer. J. Theor. Biol. 563, 111437 (2023).","journal-title":"J. Theor. Biol."},{"key":"695_CR79","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1073\/pnas.1919764117","volume":"117","author":"F Mpekris","year":"2020","unstructured":"Mpekris, F. et al. Combining microenvironment normalization strategies to improve cancer immunotherapy. Proc. Natl. Acad. Sci. USA 117, 3728\u20133737 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"695_CR80","doi-asserted-by":"publisher","first-page":"111489","DOI":"10.1016\/j.jtbi.2023.111489","volume":"568","author":"L Xue","year":"2023","unstructured":"Xue, L., Zhang, H., Zheng, X., Sun, W. & Lei, J. Treatment of melanoma with dendritic cell vaccines and immune checkpoint inhibitors: a mathematical modeling study. J. Theor. Biol. 568, 111489 (2023).","journal-title":"J. Theor. Biol."},{"key":"695_CR81","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.mce.2015.12.007","volume":"422","author":"KE Johnson","year":"2016","unstructured":"Johnson, K. E. et al. Biological activity and in vivo half-life of pro-activin A in male rats. Mol. Cell. Endocrinol. 422, 84\u201392 (2016).","journal-title":"Mol. Cell. Endocrinol."}],"container-title":["npj Systems Biology and Applications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41540-026-00695-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-026-00695-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-026-00695-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T01:03:56Z","timestamp":1781571836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41540-026-00695-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["695"],"URL":"https:\/\/doi.org\/10.1038\/s41540-026-00695-2","relation":{},"ISSN":["2056-7189"],"issn-type":[{"value":"2056-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}